Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
0.00%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 782 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
ENDRA Life Sciences Inc.
Market Cap
$8.00M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.96M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$8.06M
Gross Margin
0.00%
TTM Avg
-261.58%
3Y Avg
-106.09%
5Y Avg
-70.73%
Market Cap
$8.18M
Gross Margin
N/A
TTM Avg
-2933.43%
3Y Avg
-1696.98%
5Y Avg
-1166.77%
Market Cap
$7.70M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$8.46M
Gross Margin
18.37%
TTM Avg
19.16%
3Y Avg
20.84%
5Y Avg
23.00%
Market Cap
$8.47M
Gross Margin
-41.30%
TTM Avg
-15.77%
3Y Avg
-3.50%
5Y Avg
-3.50%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ENDRA Life Sciences Inc. (NDRA) | $8.00M | 0.00% | 0.00% | 0.00% | 0.00% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.96M | 0.00% | 0.00% | 0.00% | 0.00% |
| GT Biopharma, Inc. (GTBP)vs › | $8.05M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.06M | 0.00% | -261.58% | -106.09% | -70.73% |
| HeartSciences Inc. (HSCS)vs › | $8.18M | N/A | -2933.43% | -1696.98% | -1166.77% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.70M | 0.00% | 0.00% | 0.00% | 0.00% |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.46M | 18.37% | 19.16% | 20.84% | 23.00% |
| DataMEDS AI, Inc. (MEDS)vs › | $8.47M | -41.30% | -15.77% | -3.50% | -3.50% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | 14.92% | 28.44% | 28.69% | 27.44% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 54.96% |
| 2017-09-30 | 58.79% |
| 2017-06-30 | 10.98% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 54.25% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 50.42% |
| 2015-09-30 | 41.88% |
| 2015-06-30 | 85.59% |
| 2015-03-31 | 75.75% |
